Leading the Scientific Frontier
BioModifying was founded in 2021 by a team of biophysicists, cellular immunologists, and molecular geneticists from MIT and Harvard. Our mission is to accelerate the transition from symptom management to root-cause molecular modification.
Our Advisory Board
- Dr. Helena Vance, PhD — Professor of Molecular Genetics. Pioneer in high-fidelity CRISPR-Cas nucleases.
- Marcus Thorne, MD — Chief of Immunotherapy at Boston Clinical Center. Leader in allogeneic NK cell development.
- Dr. Sanjay Patel, PhD — Former Director of Translation Science. Specialist in lipid nanoparticle formulation and pharmacology.